Novavax Launches Enrolment in Early-stage Trial of Bird Flu Vaccine

Novavax is enrolling patients in a second Phase 1 clinical trial of a vaccine that could prevent a potential bird flu pandemic.

Novavax has started enrolment in a second Phase 1 clinical trial of a vaccine that could prevent a potential bird flu pandemic.

The aim of the trial is to test the safety of the monovalent virus-like particle (VLP) vaccine, which Novavax is developing under a contract with the US Department of Health and Human Services's Biomedical Advanced Research and Development Authority.

The placebo-controlled, observer-blind trial will also determine the vaccine's immunogenicity, with and without the use of an undisclosed adjuvant.

Novavax is enrolling 333 healthy patients in the trial, each of whom will be randomised into one of six treatment groups, including varying doses of the A/H5N1 VLP vaccine